CIK 0001527728 · Non-accelerated filer<br>Smaller reporting company
Lunai Bioworks Inc.
Sign in to watch- Ticker
- LNAI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 452259340
- Phone
- 45 39179840
- Business address
- CENTURY CITY MEDICAL PLAZA, 2080 CENTURY CITY EAST, SUITE 906 LOS ANGELES, CA, 90067
- Former names
- RENOVARO INC., RENOVARO BIOSCIENCES INC., Enochian Biosciences Inc, DanDrit Biotech USA, Inc., Putnam Hills Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-20 | Sindlev Rene Director | Option exercise · Warrant (Right to Buy) | −471,699 | 471,698 | ||
| 2024-02-13 | Abildgaard Ole 10% owner | Conversion | +3,436,190 | 7,898,482 | ||
| 2024-02-13 | Abildgaard Ole 10% owner | Conversion · Series A Convertible Preferred Stock | −343,619 | 0 | ||
| 2024-02-13 | Binette Francois COO and Executive VP for R&D | Returned to the company · Option to Purchase Common Stock | −65,000 | 0 | ||
| 2024-02-13 | Binette Francois COO and Executive VP for R&D | Grant or award · Option to Purchase Common Stock | +65,000 | 65,000 | ||
| 2024-02-13 | Binette Francois COO and Executive VP for R&D | Returned to the company · Option to Purchase Common Stock | −65,000 | 0 | ||
| 2024-02-13 | Binette Francois COO and Executive VP for R&D | Grant or award · Option to Purchase Common Stock | +65,000 | 65,000 | ||
| 2024-02-13 | Binette Francois COO and Executive VP for R&D | Returned to the company · Option to Purchase Common Stock | −40,000 | 0 | ||
| 2024-02-13 | Binette Francois COO and Executive VP for R&D | Grant or award · Option to Purchase Common Stock | +40,000 | 40,000 | ||
| 2024-02-13 | Puche Luisa Chief Financial Officer | Returned to the company · Option to Purchase Common Stock | −60,000 | 0 | ||
| 2024-02-13 | Puche Luisa Chief Financial Officer | Grant or award · Option to Purchase Common Stock | +60,000 | 60,000 | ||
| 2024-02-13 | Puche Luisa Chief Financial Officer | Returned to the company · Option to Purchase Common Stock | −60,000 | 0 | ||
| 2024-02-13 | Puche Luisa Chief Financial Officer | Grant or award · Option to Purchase Common Stock | +60,000 | 60,000 | ||
| 2024-02-13 | Puche Luisa Chief Financial Officer | Returned to the company · Option to Purchase Common Stock | −75,000 | 0 | ||
| 2024-02-13 | Puche Luisa Chief Financial Officer | Grant or award · Option to Purchase Common Stock | +75,000 | 75,000 | ||
| 2024-02-13 | Puche Luisa Chief Financial Officer | Returned to the company · Option to Purchase Common Stock | −80,000 | 0 | ||
| 2024-02-13 | Puche Luisa Chief Financial Officer | Grant or award · Option to Purchase Common Stock | +80,000 | 80,000 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Returned to the company · Option to Purchase Common Stock | −7,563 | 0 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Grant or award · Option to Purchase Common Stock | +7,563 | 7,563 | ||
| 2024-02-13 | Dybul Mark Chief Executive Officer | Returned to the company · Option to Purchase Common Stock | −5,226 | 0 |
Page 3 of 10 · 198 trades